הלוואות ואשראי לטווח ארוך של החברה: OmniAb Corp (OABI)

OmniAb, Inc. (OABI) generates revenue by licensing GMO animals for antibody creation, receiving payments from partners. The asset's price trajectory on GURU.Markets is fixed at 0.01. The OmniAb system, which automates analysis and documentation, drives efficiency gains. Meanwhile, the company relies on external cloud resources and third-party software implementation to maintain its focus on innovation.

Long-term debt reflects the aggregate of financial obligations with a maturity exceeding one year, determining the issuer's credit stability. The dynamics of the business's long-term borrowed capital level on the GURU.Markets platform allow for an assessment of the balance between investment leverage and default risks. This metric aggregates all long-term loans and bonds, capturing the volume of external financing. For OmniAb, Inc. (OABI), these funds are directed toward the development of sustainable microfluidic IT technologies and compliance with stringent bioethical standards.